ArticleFrontiers in bioengineering and biotechnology2026
Activated platelet rich plasma modulates the proliferation, apoptosis and matrix synthesis driven by growth factors in osteoarthritic chondrocytes: an
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Activated platelet-rich plasma (aPRP) reduces inflammation and promotes regeneration in osteoarthritic knee joints. It may exert therapeutic effects on osteoarthritic chondrocytes (OACs) compared with healthy chondrocytes (HCs) by promoting cell proliferation, reducing autophagy-related vesicles and inhibiting apoptosis through modulation of intracellular signaling pathways. The aim of this study was therefore to evaluate cell viability, apoptotic fate, extracellular matrix protein expression (collagen type II (COL2A1) and aggrecan (ACAN)), autophagy-related vesicle production, and growth factor profiles, including TGF-β and PDGF-BB, in HCs and OACs. Methods: Mechanically aPRP-S and PRP-G using mini-beads, leukocyte-rich L-PRP, leukocyte-poor P-PRP and platelet-rich in growth factors (PRGF) were co-cultured with HCs and OACs for real-time proliferation analysis, apoptosis by flow cytometry, autophagy and related intracellular markers through immunofluorescent labeling, and the secretome profile by ELISA, aligned with their effective dose (ED50) and optimal ED50 time point. Results: aPRPs at 2.7% in 2 h and PRGF at 1.8% in 3 h induced proliferation of OACs. PRGF reduced the apoptotic cell ratios of OACs. aPRPs and PRGF promoted COL2A1 and ACAN protein synthesis. Discussion: The induction of proliferation of the OACs is a promising result that can be translated to clinical applications. aPRPs may have a stimulatory role in OACs. This role can be dose and preparation protocol dependent. aPRPs and PRGF can be preferred to stimulate COL2A1 synthesis and reduce apoptotic cell ratios in cultured OACs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.